Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1HP for Tuberculosis Prevention in Children With and Without HIV
NCT07124559Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 6
01
Overview
A Phase 2 trial of rifapentine in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2026; status: recruiting.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07124559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124559.